SKIN
CANCER
CONNECT
November 2022
NOVEMBER 2022
DATA PRESENTED AT THE 42ND ANNUAL FALL CLINICAL DERMATOLOGY CONFERENCE®
The 42nd Annual Fall Clinical Dermatology Conference® took place from October 20-23 in Las Vegas, Nevada. New data from Castle's skin cancer tests was presented including new DecisionDx-Melanoma data from the NCI SEER program, new DecisionDx-SCC data from the prospective Clinical Utility and Health Outcomes Study (UTILISE), and a clinical impact study of MyPath Melanoma and DiffDx-Melanoma testing to guide surgical excisions and enhance management plan confidence.
RESEARCH & DEVELOPMENT
One Test Helps Inform Two Key Clinical Decisions in the Management of Melanoma
Authored by Dr. Aaron Farberg, this article in Dermatology Times provides a comprehensive overview of current staging guidelines and DecisionDx-Melanoma testing, reviews a real-world case study, and shares impactful evidence supporting use of the test to guide patient management decisions.
RESEARCH & DEVELOPMENT
Poster Presentation Highlights Initial Data From DECIDE Study
The 19th International Congress of the Society for Melanoma Research (SMR) was held in Edinburgh, United Kingdom (Oct 17-20). At this meeting, Castle presented a poster which highlights the initial data from the DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE) study.
CASE STUDY OF THE MONTH
Atypical Melanocytic Proliferation on Sensitive Preauricular Cheek
A 65-year-old male presents with an atypical melanocytic proliferation near the left ear. Four sites of basal cell carcinoma and seborrheic keratosis were taken at the same visit.